{"nctId":"NCT00764790","briefTitle":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","startDateStruct":{"date":"2008-10-01"},"conditions":["Influenza"],"count":3317,"armGroups":[{"label":"Fluarix Dose A Group","type":"EXPERIMENTAL","interventionNames":["Biological: Fluarix"]},{"label":"Fluarix Dose B Group","type":"EXPERIMENTAL","interventionNames":["Biological: Fluarix"]},{"label":"Fluzone Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Fluzone"]}],"interventions":[{"name":"Fluarix","otherNames":[]},{"name":"Fluzone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.\n* Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.\n* Written informed consent obtained from the subject's parent/guardian.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.\n* History of hypersensitivity to any vaccine.\n* History of allergy or reactions likely to be exacerbated by any component of the vaccine.\n* Acute disease at the time of enrolment.\n* History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.\n* Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.\n* Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"35 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains","description":"GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.\n\nPost-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"10.6","spread":null},{"groupId":"OG002","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.1","spread":null},{"groupId":"OG001","value":"131.6","spread":null},{"groupId":"OG002","value":"232.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"11.2","spread":null},{"groupId":"OG002","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.6","spread":null},{"groupId":"OG001","value":"158.7","spread":null},{"groupId":"OG002","value":"280.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"8.9","spread":null},{"groupId":"OG002","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113.0","spread":null},{"groupId":"OG001","value":"164.4","spread":null},{"groupId":"OG002","value":"176.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted","description":"Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer \\< 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.\n\nPost-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"636","spread":null},{"groupId":"OG001","value":"699","spread":null},{"groupId":"OG002","value":"929","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"747","spread":null},{"groupId":"OG001","value":"808","spread":null},{"groupId":"OG002","value":"988","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"812","spread":null},{"groupId":"OG001","value":"864","spread":null},{"groupId":"OG002","value":"904","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects","description":"A seroprotected subject is a subject with a serum anti-HA titer\n\n≥ 1:40\n\nPost-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"186","spread":null},{"groupId":"OG002","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"699","spread":null},{"groupId":"OG001","value":"754","spread":null},{"groupId":"OG002","value":"986","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"193","spread":null},{"groupId":"OG002","value":"214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"788","spread":null},{"groupId":"OG001","value":"846","spread":null},{"groupId":"OG002","value":"1012","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"181","spread":null},{"groupId":"OG002","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"872","spread":null},{"groupId":"OG001","value":"902","spread":null},{"groupId":"OG002","value":"935","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Factor","description":"Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0).\n\nPost-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"21.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"14.2","spread":null},{"groupId":"OG002","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"18.4","spread":null},{"groupId":"OG002","value":"21.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"406","spread":null},{"groupId":"OG002","value":"363","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"249","spread":null},{"groupId":"OG002","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"170","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited General Symptoms","description":"Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"317","spread":null},{"groupId":"OG002","value":"298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"387","spread":null},{"groupId":"OG002","value":"375","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"281","spread":null},{"groupId":"OG001","value":"273","spread":null},{"groupId":"OG002","value":"270","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Adverse Events (AE)","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"565","spread":null},{"groupId":"OG001","value":"541","spread":null},{"groupId":"OG002","value":"562","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)","description":"An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.\n\nNOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Rare Serious Events","description":"Rare serious events have an occurrence rate of 1/300 (0.3%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":1107},"commonTop":["Pain","Irritability","Drowsiness","Loss of appetite","Redness"]}}}